Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials.

OBJECTIVES

Radioiodine-refractory differentiated thyroid cancer (RAI-rDTC) has frequently been associated with poor prognosis. We conducted a meta-analysis of published randomized controlled trials to evaluate multi-kinase inhibitors' efficacy and safety profile treatment.

METHODS

A comprehensive search was conducted using PubMed, Embase, Cochrane, and Medline databases. The quality of literature and trial risk of bias was assessed using the Cochrane risk of bias tool, while the results of progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated using RevMan5.3 software.

RESULTS

Treatment with MKIs significantly improved PFS and OS, but AEs were significantly higher than those in the control group (). The studies demonstrated the median PFS (HR 0.30, 95% CI: 0.18-0.50, ) and OS (HR 0.70, 95% CI: 0.57-0.88, ) in RAI-rDTC patients treated with MKIs, and the median PFS of papillary thyroid carcinoma (HR0.28, 95% CI: 0.22-0.37, ) along with follicular thyroid carcinoma (HR0.14, 95%CI 0.09-0.24, ) were extended.

CONCLUSION

MKIs significantly prolonged PFS and OS in patients with RAI-rDTC (). Our recommendation is to use MKIs carefully in patients after evaluating their health status to maximize treatment benefits and minimize adverse effects.